XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Per Share Information
9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Per Share Information
9. PER SHARE INFORMATION:
The amounts used to compute basic and diluted earnings per share attributable to common stock consisted of the following (in thousands):
Three Months EndedNine Months Ended
September 30,September 30,
2022202120222021
Amounts attributable to common stock:
Net income attributable to common stock$155,956 $174,365 $328,617 $381,159 
Weighted average shares:
Weighted average shares outstanding for basic earnings per share attributable to common stock143,353 140,008 143,581 140,134 
Effect of dilutive unvested non-participating stock-based awards4,325 4,296 4,515 4,314 
Weighted average shares outstanding for diluted earnings per share attributable to common stock147,678 144,304 148,096 144,448 
Basic and diluted earnings per share attributable to common stock are computed using the weighted average number of shares of common stock outstanding during the applicable period. Additionally, unvested stock-based awards that contain non-forfeitable rights to dividends or dividend equivalents (participating securities) have been included in the calculation of basic and diluted earnings per share attributable to common stock for the portion of the periods that the awards were outstanding. Weighted average shares outstanding for basic and diluted earnings per share attributable to common stock included 0.1 million and 0.5 million weighted average participating securities for the three months ended September 30, 2022 and 2021 and 0.2 million and 0.7 million weighted average participating securities for the nine months ended September 30, 2022 and 2021.
For purposes of calculating diluted earnings per share attributable to common stock, there were no adjustments required to derive Quanta’s net income attributable to common stock. Diluted earnings per share attributable to common stock is computed using the weighted average number of shares of common stock outstanding during the period adjusted for all potentially dilutive common stock equivalents, except in cases where the effect of the common stock equivalents would be antidilutive.